Cascade Investment Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$301K Sell
4,965
-600
-11% -$35K 0.2% 116
2025
Q4
$300K Sell
5,565
-399
-7% -$19.2K 0.2% 107
2025
Q3
$269K Sell
5,964
-150
-2% -$7K 0.18% 117
2025
Q2
$283K Buy
6,114
+400
+7% +$19.6K 0.2% 108
2025
Q1
$348K Hold
5,714
0.27% 87
2024
Q4
$323K Hold
5,714
0.23% 102
2024
Q3
$296K Sell
5,714
-650
-10% -$30.5K 0.22% 105
2024
Q2
$264K Buy
+6,364
New +$285K 0.21% 107
2023
Q1
Sell
-2,787
Closed -$201K 122
2022
Q4
$201K Buy
+2,787
New +$210K 0.21% 115

Other funds holding BMY

Cascade Investment Group's BMY Position: Q1 2026 in Review

Cascade Investment Group reduced its Bristol-Myers Squibb (BMY) stake by 11% in Q1 2026, selling an estimated $35K and leaving 4,965 shares worth $301K. The position accounts for 0.2% of the portfolio, ranked #116.

Cascade Investment Group first reported a position in BMY in Q4 2022 and has held it in 9 quarters since. The position peaked at $348K in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Cascade Investment Group held 4,965 shares of Bristol-Myers Squibb worth $301K as of Q1 2026.
  • Cascade Investment Group sold 600 Bristol-Myers Squibb shares in Q1 2026, an estimated $35K.
  • Bristol-Myers Squibb made up 0.2% of Cascade Investment Group's portfolio in Q1 2026, its #116 holding.
  • Cascade Investment Group first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 9 quarters since.
  • Cascade Investment Group's Bristol-Myers Squibb position peaked at $348K in Q1 2025.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cascade Investment Group's 13F filing for Q1 2026, filed 13 May 2026.